Nervous System Diseases

Symptoms and General Pathology

All Conditions

Rare Diseases

Neuralgia

Pain

Nociceptive Pain

Peripheral Nervous System Diseases

Neuromuscular Diseases

Neurologic Manifestations

Chronic Graft Versus Host Disease

Analgesics

Central Nervous System Depressants

All Drugs and Chemicals

Adjuvants, Anesthesia

Oxycodone

Morphine

Analgesics, Opioid

Oxymorphone

Narcotics

Anesthetics

Oxymorphone ER

Marco Pappagallo

Marco Pappagallo, MD

This project will explore the safety and feasibility of performing a successful intravenous patient controlled analgesia (IV PCA) Oxymorphone titration and conversion to oral ER Oxymorphone (extended release or OPANA ER) in the outpatient setting.

This project will enroll 12 volunteers who suffer from chronic pain. Potential participants must be on one of the following therapies:

* Long acting morphine
* Oxycodone Participants will be asked to complete a pain diary for approximately 10 days and to stop taking their current pain medications the night before they are admitted o the GCRC. Once the patients present at the GCRC, they will be started on the IV PCA (Patient Controlled Analgesia) Oxymorphone to control their pain. Titration will take approximately a total of 8 hrs. At the end of the titration period, patients will be discharged home on OPANA ER. The oral dose will be calculated based on the IV PCA use. During the titration, patients' pain, vital and side effects will be assessed hourly until the 8th hour of the IV PCA titration.

Patients will be contacted daily by a member of the study team to assess pain and side effects. The OPANA ER dose will be adjusted as needed to adequately manage both.

If patients do not feel as though they are getting adequate pain relief, they can return to their previous medication, at which point they are considered withdrawn from the study.

Patients will undergo an exit examination 2 weeks after they were admitted to the GCRC in order to assess pain relief. In addition, a final follow-up telephone interview will take place 6 weeks after the initial 1-day stay at the GCRC. Our research staff or physicians will ask about your pain treatment and ask which Opioid medication you are currently taking.

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

Endo Pharmaceuticals

Icahn School of Medicine at Mount Sinai

Marco Pappagallo, MD, Director of Pain Research and Development

Cancer Pain

Breakthrough Pain

Fentanyl

Anesthetics, Intravenous

Anesthetics, General

* Baseline period: 7-15 episodes of breakthrough cancer pain treated with prior IR opioid medication
* Treatment period: Conversion to SL Fentanyl at a Fentanyl:Prior opioid conversion factor of 1:50 (using the estimated Morphine Sulphate Equivalent dose for the prior opioid). SL Fentanyl use was followed for 8-15 episodes of breakthrough cancer pain. SL Fentanyl dose could be titrated between episodes.

SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.

SL fentanyl

Anders Pettersson, MD, PhD

The purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl (Abstral) for treatment of breakthrough cancer pain (BTcP).

The study aims to show that in the advanced stage of cancer the individual patient already on high doses of BTcP medication will benefit from starting treatment on a higher first dose of SL fentanyl thus reducing the number of dosing steps with insufficient pain relief.

Conversion From Fast Acting Oral Opioids to Abstral®

Conversion From Fast Acting Oral Opioids to Abstral® (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain

A subject is defined as responder if the change of Pain Intensity (PI) on the Numerical Rating Scale (NRS) rated from 0 to 10, at 30 minutes (PID30) is similar or higher after the conversion to SL fentanyl compared to baseline PID30 as assessed by standard care rescue treatment of BTcP episodes.

Orexo AB

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone	NCT00945919	Chronic Nocicep... Neuropathic Pai... Non-cancer Pain	Oxymorphone ER	18 Years -	Icahn School of Medicine at Mount Sinai
Conversion From Fast Acting Oral Opioids to Abstral®	NCT01315886	Pain	SL fentanyl	18 Years -	Orexo AB
A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone	NCT00945919	Chronic Nocicep... Neuropathic Pai... Non-cancer Pain	Oxymorphone ER	18 Years -	Icahn School of Medicine at Mount Sinai
Conversion From Fast Acting Oral Opioids to Abstral®	NCT01315886	Pain	SL fentanyl	18 Years -	Orexo AB

Spots Global Cancer Trial Database for titration

Every month we try and update this database with for titration cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for titration

Every month we try and update this database with for titration cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for titration cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.